Project Grant K08AR084610
Award Date
5/1/25
Completion Date
3/31/30
Dollars Obligated
$174K
Similar Awards
The Project Grant award R01AR083543, totaling $594,600.00, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award was granted to The Research Foundation For The State University Of New York, doing business as Stony Brook University, to investigate the instructive roles of mesenchymal proteoglycans in hair follicle morphogenesis and maintenance. The key...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $401,433 from September 2023 to August 2025 to support research at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The research aims to investigate the role of protein O-GlcNAcylation in regulating keratinocyte function and its impact on skin...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,700 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the University of California, Irvine (UC Irvine) to develop a novel therapeutic approach for improving angiogenesis and wound healing. The project aims to deliver apoptotic neutrophils within a degradable hydrogel scaffold to stimulate macrophages and promote their angiogenic signaling and tissue repair without...
This $230,212 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research by Rockefeller University to investigate how the immune system drives stem cell heterogeneity in the skin. The key research goals of this project are to: 1) Determine how direct contact with dendritic epidermal T cells mediates functional stem cell specification...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $295,294 to Biotherapeutics, Inc. for the development of a novel first-in-class topical immunoregulatory therapeutic for the treatment of plaque psoriasis. The key objectives are to: 1) evaluate the permeability and long-term stability of the topical drug product formulation, 2) compare the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $383,570 to Temple University to conduct research on interleukin-36 (IL-36) cytokine activation and inactivation mechanisms. The project aims to improve understanding of IL-36 functions and their role in inflammatory conditions, such as atopic dermatitis, psoriasis, and skin infections,...
This $198,782 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will enable Duke University to develop genetically modified 3D human reconstructed epidermis (RHE) models. The goal is to investigate interactions between the skin microbiome and skin cell populations, including keratinocytes and fibroblasts, using CRISPR/Cas9 knockouts of key skin...
This federal Project Grant award, valued at $242,310.00, was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports research at Rockefeller University to investigate the long-term impacts of allergic "type 2" skin inflammation on epithelial stem cells, which play a key role in tissue repair and adaptation. Specifically, the research aims to...
This federal Project Grant award of $526,041, made by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a relaxin-loaded hydrogel treatment for hypertrophic scars. The primary objectives are to: Determine the mechanism of action of relaxin-2 (RLX-2) in reducing fibrotic scarring through in vitro and ex vvivo studies. Develop an RLX-2-loaded hydrogel...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $384,250 to the University of Alabama at Birmingham (UAB) to elucidate the mechanisms by which immune checkpoint signaling between PD-1 and PD-L1 regulates the interactions between immune cells and stem cells, with a focus on melanocyte stem cells and their role in hair pigmentation. The key objectives of...